Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Clinician shows a model of the female reproductive system
Current clinical screening methods for cervical cancer and precancerous lesions rely heavily on cytology techniques which can be time-consuming and prone to misdiagnosis.

Immunolabeling New Biomarker May Help in Early Detection of Cervical Precancerous Lesions

HMGB3 could effectively label the precancerous cells at different pathological stages

Hefei Institutes of Physical Science
Published:Jun 08, 2023
|2 min read
Register for free to listen to this article
Listen with Speechify

Yang Wulin, PhD, professor at the Center of Medical Physics and Technology at Hefei Institutes of Physical Science, and his research group recently developed a new technology for early screening and monitoring of cervical precancerous lesions. The results were published in Genes & Diseases.

Cervical cancer ranks as the second most prevalent cancer in women globally, with persistent human papillomavirus (HPV) infection as its leading cause. The precancerous lesions induced by persistent HPV infection are referred to as intraepithelial neoplasia and may progress to invasive cancer if left untreated. 

Current clinical screening methods for cervical cancer and precancerous lesions rely heavily on cervical cytology techniques such as Papanicolaou smear, thin-layer cytology, and p16/Ki-67 double staining technologies. However, identifying diseased cells using these methods can be time-consuming, and prone to misdiagnosis. Therefore, searching for new markers that can improve the shortcomings of current screening techniques is paramount.

"We used gene chip data combined with immunohistochemistry and immunocytochemistry to screen out the dominant candidate markers, HMGB3, from a large number of differentially expressed genes," said Wulin.

HMGB3's advantage over traditional markers

An immunohistochemistry analysis study showed that HMGB3 could effectively label the diseased cells at different pathological stages. Firstly, the positive labeling rate of HMGB3 for CIN1—the earliest stage of cervical precancerous lesions—was more than 95 percent, which was much higher than the 33 percent positive rate of the traditional marker, p16.

Secondly, HMGB3 can be used to mark basal cells in reactive hyperplasia of the cervix. Follow-up analysis revealed that monitoring its expression changes can predict whether simple hyperplasia cases will progress to intraepithelial lesions or spontaneous regression.

In addition, immunocytochemistry experiments also verified the ability of HMGB3 in labeling the diseased cells in the cervical exfoliated cell samples to achieve pathological stage stratification.

The immunolabeling approach developed in this study using the HMGB3 marker is expected to be a cutting-edge cervical cancer detection tool. This technology would help to detect precancerous lesions in the cervix, thus increasing human health, according to the team. 

- This press release was originally published on the Hefei Institutes of Physical Science website